TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths.
• Programmed death-ligand 1 (PD-L1) is a key immune checkpoint target in cancer therapy.
• The role of the TUSC2 tumor suppressor gene in regulating PD-L1 in NSCLC is not fully understood.

Purpose of the Study:

• To investigate the effect of TUSC2 gene expression on PD-L1 levels in NSCLC cells.
• To elucidate the molecular mechanisms by which TUSC2 influences PD-L1 expression, particularly its relationship with the mTOR pathway.
• To assess the potential of TUSC2 as an adjunct therapy in combination with immune checkpoint inhibitors.

Main Methods:

• Utilized TUSC2-deficient NSCLC cell lines to study TUSC2 re-expression effects.
• Employed rapamycin, an mTOR inhibitor, as a comparative treatment.
• Performed microarray mRNA expression analysis to identify TUSC2-regulated genes.
• Assessed PD-L1 expression in the presence and absence of interferon-gamma (IFN-γ).

Main Results:

• TUSC2 re-expression in NSCLC cells significantly decreased PD-L1 expression and inhibited mTOR activity.
• Both TUSC2 overexpression and rapamycin treatment led to comparable reductions in PD-L1 and phosphorylation of p70 and SK6, indicating a shared mTOR target.
• TUSC2 upregulated genes negatively regulating the mTOR pathway and prevented IFN-γ-induced PD-L1 increase in lung cancer cells.

Conclusions:

• TUSC2 effectively reduces PD-L1 expression in lung cancer cells through mTOR pathway inhibition.
• TUSC2 modulates the tumor microenvironment by downregulating PD-L1.
• TUSC2 holds potential as a therapeutic agent to augment the efficacy of immune checkpoint inhibitors in NSCLC treatment.